Briefing documents released Tuesday show that the Qnexa, which is a combination of Phentermine (one of the ingredients in FenPhen) and Topiramate (a seizure med that may increase suicide market as Topamax), may have harmful psychiatric and cardiovascular side effects.
Qnexa is being review by an agency panel Thursday. The main concern currently is that there hasn't been enough testing among pregnant women, which may lead to an increase in fetal deformities.
Rheingold, Giuffra, Ruffo & Plotkin LLP was deeply involved in the FenPhen litigation and if this drug recieves approval we will be following it closely. Contact us for a free consultation if you think you have been injured as a result of a prescription drug.